Recent Release | 13 Jul 2020
Trade and transport margins in pharmaceuticals and other R&D-intensive industries
Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).
Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.
Tags:
You may be interested in
Post
Oxford Economics Launches Global Cities Index 2025
Oxford Economics is proud to launch the 2025 update of the Global Cities Index, which offers an evaluation of the world's 1,000 largest urban economies.
Find Out More
Post
Oxford Economics Launches TradePrism on Snowflake Marketplace to Deliver Global Trade Intelligence in Near Real-Time
Oxford Economics, a global leader in economic forecasting and data analytics, has announced the launch of its TradePrism platform on Snowflake Marketplace, enabling businesses to seamlessly access and integrate trade data and forecasts into their operations in near real-time.
Find Out More
Post
Oxford Economics Expands Regional Presence with the Launch of Japanese Website
Oxford Economics, the world’s leading independent economic advisory firm, is excited to announce the launch of its new Japanese website. This important milestone reflects our ongoing commitment to broadening our presence in key regional markets and strengthening our ability to provide localised, high-quality economic insights to businesses and decision-makers in Japan.
Find Out More